Immunic advances ‘potentially groundbreaking’ MS therapy vidofludimus calcium during Q1
Immunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset, nuclear receptor related 1 (Nurr1) activator…
1,049€
1,94%
Echtzeit-Aktienkurs Immunic Inc.
Bid:
Ask:
Nachrichten zur Immunic Inc. Aktie
Immunic publishes extended data from Phase 2 MS trial in peer-reviewed journal
Immunic Inc (NASDAQ:IMUX) has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in…
Immunic granted patent for specific polymorph of vidofludimus calcium in US
Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium,…
Immunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trials
Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its…